Heart transplantation across the antibodies against HLA and ABO

Dragan Bucin,Sune Johansson,Torsten Malm,Peeter Jogi,Jens Johansson,Per Westrin,Lars O Lindberg,Ann-Kristin Olsson,Jan Gelberg,Valeria Peres,Solweig Harling,Rolf Bennhagen,Bjorn Kornhall,Bjorn Ekmehag,Jan Kurkus,Gisela Otto
DOI: https://doi.org/10.1111/j.1432-2277.2005.00260.x
2006-03-01
Transplant International
Abstract:We have intentionally performed heart transplantation in a 5-year-old child, despite the most unfavourable risk factors for patient survival; the presence of high level of antibodies against donor's human leucocyte antigen (HLA) class I/II and blood group antigens. Pretransplant treatment by mycophenolate mofetil, prednisolone, tacrolimus, intravenous immunoglobulin, rituximab, protein-A immunoadsorption (IA) and plasma exchange reduced antibody titres against the donor's lymphocytes from 128 to 16 and against the donor's blood group antigen from 256 to 0. The patient was urgently transplanted with a heart from an ABO incompatible donor (A(1) to O). A standard triple-drug immunosuppressive protocol was used. No hyperacute rejection was seen. Antibodies against the donor's HLA antigens remained at a low level despite three acute rejections. Rising anti-A(1) blood group antibodies preceded the second rejection and were reduced by two blood group-specific IAs and remained at a low level. The patient is doing well despite the persistence of donor-reactive antibodies.
surgery,transplantation
What problem does this paper attempt to address?